Owlet, Inc. OWLT

5.04 (0.03) (0.59%) as of 25 Sep
Market cap
$148.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years

Insider Decisions

Total sells 0.03
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — 2 — — — — — — — —
Insider Ownership 44.59%

Capital & Financial Ratios

Market Cap 148.15
Revenue 114.86
Net Income (9.66)
Free Cash Flow (9.86)
Net Debt (19.48)
Current Ratio 1.64
Debt/Equity 0.46
P/E ratio 0.00
P/S ratio 1.25
P/B ratio 6.21
Past 5Y EPS Growth 25.86%
This Y EPS Growth 89.61%
Next Y EPS Growth 101.39%
Next 5Y EPS Growth 56.32%
in millions of $

Dividends

Payout Ratio 0.00
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 17 21 41 37
Receivables 14 12 23 33
Inventory 6 11 15 16
Other — — — —
40 46 82 88
2023 2024 2025 Q'26
Payables 14 11 12 12
ST’ Debt 15 7 11 17
Other — — — —
45 36 44 54
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — 6.99% 15.17%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue

Mar Jun Sep Dec Year
’26 22 34 — — —
’25 21 26 32 27 106
’24 15 21 22 20 78
’23 11 13 9 21 54
’22 22 18 17 12 69
’21 22 25 32 (3) 76
in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (5) 0 — — —
’25 (6) (2) (2) 0 (11)
’24 (3) (3) (7) 3 (11)
’23 (9) (7) (5) (2) (24)
’22 (27) (28) (16) (10) (81)
’21 (7) (9) (19) (6) (41)
in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

Mar Jun Sep Dec Year
’26 (5) (1) — — —
’25 (6) (2) (2) (1) (12)
’24 (3) (3) (8) 3 (12)
’23 (9) (7) (5) (2) (24)
’22 (28) (29) (16) (10) (83)
’21 (7) (9) (20) (6) (43)
in millions of $ · fiscal quarters ending in the months shown

EPS

Mar Jun Sep Dec Year
’26 (0.25) (0.05) — — —
’25 0.11 (2.37) (0.06) (0.39) (2.31)
’24 (0.51) (0.30) (0.61) (0.63) (1.57)
’23 (1.54) (1.19) (0.84) (0.97) (4.53)
’22 (3.64) (1.54) (2.38) (2.38) (9.94)
’21 (4.95) (3.32) (5.04) (3.08) (15.83)
fiscal quarters ending in the months shown

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — 134.96 34.02 7.52 2.52 3.20 2.75

Analyst estimates 2026–2028

Powerpack
Low Price
— — — — 143.92 161.84 74.90 9.69 7.50 16.94
High Price
— — — — 3 200 106 76 85 114
Employees
— — — — 25 0 1 1 1 1
Revenue/Emp
— — — — 75 76 69 54 78 106
Revenue
— — — — 47.58% 46.23% 33.69% 41.82% 50.36% 50.64%
Gross Margin
— — — — (11) (72) (79) (33) (12) (40)
EBT
— — — — (13.93%) (94.50%) (114.60%) (60.90%) (15.99%) (37.51%)
EBT Margin
— 0 — — (11) (72) (79) (33) (13) (40)
Net Income
— — — — 1 1 3 2 4 3
Depreciation
— — — — 48.10 16.80 8.70 6.53 7.13 5.84
Revenue/Sh
— — — — (6.71) (15.83) (9.94) (4.53) (1.57) (2.31)
Earnings/Sh
— — — — (0.08) (8.99) (10.24) (2.84) (1.02) (0.60)
Cash Flow/Sh
— — — — (0.67) (0.45) (0.20) (0.01) (0.07) (0.05)
Capex/Sh
— — — — (0.76) (9.43) (10.43) (2.85) (1.09) (0.65)
Free CF/Sh
— — — — (13.28) 12.23 (1.34) (3.59) (1.93) 1.72
Book Value/Sh
— — — — 2 5 8 8 11 18
Shares
— — — — 0.00 0.00 0.00 0.00 0.00 0.00
PE Ratio
— — — — 0.00 2.22 0.92 0.88 0.62 2.77
PS Ratio
— — — — 20.50 3.06 0.00 0.00 0.00 15.38
PB Ratio
— — — — 0.00 1.19 1.00 0.87 0.51 2.51
EV/Sales
— — — — 0.00 (2.12) (0.84) (1.98) (3.32) (22.58)
EV/FCF
— — — — 0 (41) (81) (24) (11) (11)
Op' Cash Flow
— — — — (1) (2) (2) 0 (1) (1)
Capex
— — — — (1) (43) (83) (24) (12) (12)
FCF
— — — — (10) 67 (15) (5) 10 38
Working Cap'
— — — — 22 17 15 15 12 13
Total Debt
— — — — 5 (79) 4 (1) (9) (28)
Net Debt
— — — — (21) 55 (11) (30) (21) 31
Sh' Equity
— — — — (52.45%) (79.60%) (80.08%) (73.35%) (36.77%) (61.94%)
ROA
— — — — 0.00% 0.00% 0.00% 0.00% 0.00% (168.95%)
ROIC
— — — — (8.25%) 1,118.80% (356.12%) 155.68% 51.18% 781.68%
ROE
predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Owlet, Inc. peers in Medical Devices

Company Market cap P/E Compare
QTRX Quanterix Corporation $150.4M 0.0× Compare
INGN Inogen, Inc $138.8M 0.0× Compare
LUCD Lucid Diagnostics Inc. $170.3M 0.0× Compare
QSI Quantum-Si Incorporated $172.9M 0.0× Compare
Company Market cap P/E Compare
MXCT MaxCyte, Inc. $122.8M 0.0× Compare
APYX Apyx Medical Corporation $119.2M 0.0× Compare
RXST RxSight, Inc. $196.7M 0.0× Compare
PROF Profound Medical $204.6M 0.0× Compare

All 149 Medical Devices stocks →

Owlet, Inc. (OWLT) key facts

  • Owlet, Inc. (OWLT) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • Owlet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $105.7 million, up 35.4% from fiscal 2024.
  • As of September 25, 2026, OWLT traded at $5.04, a market capitalization of $148.2 million.
  • Return on equity was 781.7% and debt-to-equity 0.46.

Source: company filings (standardised) and stockrow calculations.

Owlet, Inc. (OWLT) Latest News

News by impact score

Fine-tune

18 Aug

4 transcript

Owlet (OWLT) released its Q2 2026 earnings call transcript detailing financial results, operational updates and executive outlook. Q2 2026 earnings figures and forward guidance disclosed during the call can materially shift stock valuation and investor positioning.

12 Aug

4

Owlet Inc posted record Q2 2026 revenue and outlined plans for strategic AI expansion. Record revenue and AI initiatives signal major strategic progress that can shift company trajectory and investor views.

3 transcript

Owlet, Inc. held Q2 2026 earnings call covering revenue, net loss, product sales, cash position and forward guidance. Quarterly earnings and guidance directly inform near-term financial expectations and investor positioning.

11 Aug

4

Owlet, Inc. announced its financial results for the second quarter of 2026. Quarterly earnings releases typically drive significant stock price movements and investor reassessment of company trajectory.

3

Owlet held Q2 earnings call and shared financial results along with operational and strategic updates. Q2 earnings call supplies financial metrics and strategy details that moderately shift near-term sentiment and valuation.

3

Owlet beat Q2 earnings and revenue estimates. Q2 earnings and revenue beats indicate better than expected financial results that may lift near-term market performance.

30 Jun

3

Owlet secures a new $25 million credit facility from Wells Fargo that significantly reduces borrowing costs and enhances financial flexibility. Improved credit terms strengthen Owlet's balance sheet and operational flexibility.

14 May

4

Owlet, Inc. (OWLT) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights directly influence OWLT's financial performance, investor sentiment, and stock trajectory through reported results and guidance.

13 May

4

Owlet, Inc. (OWLT) stock plunged 60% in the first quarter due to factors outlined in recent analysis. OWLT's 60% Q1 stock crash reflects major setbacks likely to alter its financial trajectory and investor sentiment significantly.

12 May

4

Owlet CEO Kurt Workman shares key takeaways from the company's Q1 earnings report, highlighting firm performance and future outlook. CEO's Q1 earnings takeaways signal major shifts in financial performance and strategy, poised to alter OWLT's trajectory and investor sentiment.

11 May

4

Owlet launches Dream Sight™ and Dream Duo™ 3 in Australia and New Zealand, expanding its product suite with the world’s most comprehensive baby monitoring system to reach more families. New product launches in ANZ region represent a major strategic expansion enhancing market reach and competitive positioning.

3

Analysts updated estimates for Owlet, Inc. (NYSE:OWLT) following its first-quarter report, with brokers providing insights on future performance and stock outlook. Analyst updates after Q1 report can moderately influence investor sentiment and earnings expectations.

8 May

4

Owlet, Inc. (OWLT) Q1 2026 earnings call summary details quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings disclosures directly shape investor sentiment, financial projections, and stock valuation.

7 May

4

Owlet, Inc. (OWLT) announced first quarter 2026 financial results and updated its full-year 2026 guidance. Q1 2026 financial results and updated annual guidance constitute a significant financial disclosure likely to impact OWLT's trajectory and investor sentiment.

3

Owlet, Inc. (OWLT) reported a Q1 net loss but surpassed revenue estimates. Q1 loss despite revenue beat moderately influences financial performance and investor sentiment.

30 Apr

3

Owlet, Inc. (OWLT) Q1 earnings expected to decline. Expected Q1 earnings decline signals moderate pressure on financial performance and investor sentiment.

16 Apr

4

Owlet, Inc. (OWLT) launches new employer benefit program enabling companies to offer medical-grade infant health monitoring to support parents. New employer benefit program represents a major strategic B2B expansion for Owlet, potentially boosting adoption and revenue through corporate partnerships.

7 Apr

3

Owlet Dream Duo™ 3 named 'Best for Monitoring Baby's Health' in PARENTS 2026 Best for Baby Awards. Award recognition strengthens Owlet's competitive positioning in baby health monitoring and may positively influence market sentiment and sales.

6 Apr

4

Owlet, Inc. (OWLT) announces CEO transition with the board reaffirming Q1 2026 guidance and long-term growth opportunities. CEO transition signals major leadership shift with potential to alter strategic trajectory, balanced by reaffirmed guidance signaling continuity.

9 Mar

4

Owlet (OWLT) delivered record 2025 results and issued 2026 growth guidance, triggering a valuation review amid strong performance outlook. Record 2025 results and 2026 growth guidance represent major financial milestones likely to enhance investor confidence and trajectory.

7 Mar

4

Owlet (OWLT) shares dropped 37.1% after mixed 2025 results despite a raised 2026 guidance, prompting questions on whether the bull case has changed. Mixed 2025 results triggered a 37.1% stock plunge despite higher 2026 guidance, signaling major shifts in investor sentiment and trajectory.

6 Mar

4

Owlet, Inc. (OWLT) issued a disappointing outlook for 2026, forecasting weaker performance that raises concerns about future growth and profitability amid ongoing challenges. Disappointing 2026 outlook signals significant risks to OWLT's financial trajectory and investor confidence.

4

Owlet, Inc. released Q4 2025 earnings call summary detailing financial results, revenue growth, profitability progress, and strategic outlook for baby monitoring products. Q4 earnings summary highlights financial performance and guidance directly influencing investor sentiment and stock trajectory.

4

Owlet Inc. reported Q4 revenue of $21.1 million, up 43% year-over-year, with gross margins at 53.5%. Full-year 2023 revenue hit $66.8 million, a 53% increase. Positive adjusted EBITDA achieved in Q4; profitability expected in 2024. New Dream Sock FDA-approved for all ages, expanding market. Guidance projects 2024 revenue over $80 million. Strong revenue growth, margin expansion, profitability path, and product expansions signal major positive shift in financial trajectory and investor outlook.

4

Owlet Inc (OWLT) reported record revenue and strategic expansions in Q4 2025 earnings call amid ongoing challenges. Record revenue and strategic expansions indicate major positive shifts in financial performance and growth trajectory.

3

Owlet, Inc. (OWLT) reported a narrower-than-expected Q4 loss, with revenues rising year-over-year. Narrower Q4 loss than expected and year-over-year revenue growth moderately boost financial performance and market sentiment.

5 Mar

4

Owlet reported fourth quarter and full-year 2025 financial results and initiated 2026 guidance. Quarterly results and new annual guidance directly shape investor sentiment and stock trajectory.

3

Owlet, Inc. (OWLT) reported a Q4 net loss but exceeded revenue estimates. Q4 revenue beat despite net loss moderately influences financial performance and investor sentiment.

2 Mar

3

Owlet (OWLT) stock faces buy-now-or-wait decision ahead of Q4 earnings, weighing recent performance, analyst views, and potential results impact on share price. Q4 earnings preview targets key financials likely to noticeably influence OWLT's stock trajectory and investor sentiment.

11 Feb

3

The National Advertising Division (NAD) has recommended that Nanit discontinue its claims of being the '#1 Baby Monitor' following a review prompted by Owlet, Inc. The NAD found that Nanit's advertising could mislead consumers regarding its market position. This decision may impact Nanit's marketing strategies and competitive claims in the baby monitor sector. Nanit's advertising claims could affect its competitive positioning and market perception, which may indirectly influence Owlet's performance.

stockrow.com/OWLT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com